Page 125 - Livre électronique des RFTP 2024

OVERUSE OF SHORT-ACTING BETA-2 AGONISTS

IN ASTHMATIC PATIENTS

BENABBES NARJES1, GUEZGUEZ FATMA 1,2, BARKOUS BALSAM1, BOUBAKRI SABA1,
BRIKI CHAIMA1,BEN HMID WIEME1, SAYHI AMANI1,2, GHANNOUCHI INES1,2, ROUATBI
SONIA 1,2

1 DEPARTMENT OF PHYSIOLOGY AND FUNCTIONAL EXPLORATIONS, UNIVERSITY HOSPITAL OF
FARHAT HACHED SOUSSE, TUNISIA 2 RESEARCH LABORATORY OF HEART FAILURE, LR12SP09,
UNIVERSITY HOSPITAL OF FARHAT HACHED SOUSSE, TUNISIA

INTRODUCTION

The extensive use of short-acting beta-2 agonists (SABA) for asthma relief is
common knowledge. However, overuse of SABA has been associated with
negative effects, such as increased risks of asthma attacks and exacerbations.

OBJECTIVE

This study aims to determine the clinical and functional features associated with
overuse of SABA in asthmatic patients.

METHODS

A comparative study including adult asthmatic patients was conducted in the
Physiology and functional explorations department of Farhat Hached hospital in
Sousse. A medical questionnaire was used to assess medical history and data
related to asthma. The mini-asthma quality of life questionnaire (mini-AQLQ) was
used to evaluate the quality of life. A spirometric study before and after
bronchodilator was performed and the GLI 2012 norms were applied. SABA
overuse was defined as the use of more than canister per month and subjects were
devided in two groups accordingly (G1: SABA over-users, G2: SABA normal-users).
SPSS software was used for statistical analysis.

RESULTS:
Among 63 participants, 27 patients (mean age = 43.6 years, sex ratio= 0.42) overused
their SABA inhaler. Concomitant use of inhaled corticosteroids (ICS) was observed
in 22 patients (81.5%). Among the concomitant ICS users 38.1%, had poor adherence
to treatement. Compared to G2, G1 exhibited more uncontrolled asthma (88.9% vs
38.9%, p<0.001) and depression (69.6% vs 30.6%, p=0.003). They also had a worse
quality of life regarding the total score of the mini_AQLQ (51.8±13.6 vs 65.2±21.5, p
=0.005), the emotional dimension (10.3±4.5 vs 13.5±6.1,p=0.025), the activity
dimension (15.4±5.3 vs 19±6.7, p=0.033) and the symptoms dimension (16.9±5.6 vs
21.4±7.2, p=0.009). Finally they showed more impaired lung function with lower
FEV1 (64±17 vs 74±14, P=0.018) and lower FVC (75±14 vs 83±13, p=0.023).

123 | P age